Aduro Clean Technologies Inc.
ADUR Nasdaq Chemicals & Allied Products Financials FY2024–FY2026
What Aduro Clean Technologies Inc. does
No business description yet.
- Legal name
- ADURO CLEAN TECHNOLOGIES INC.
- Fiscal year ends
- May 31, 2026
- Latest annual report
- 40-F · Aug 31, 2026
- Accession · CIK
- 0001062993-26-004744
0001863934
Revenue and margins
Aduro Clean Technologies Inc. had $0.1M of revenue in fiscal 2026, down 26.8% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$10.6M in fiscal 2026, −8,773.9% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Aduro Clean Technologies Inc. returned — to shareholders in fiscal 2026. The diluted share count rose 18.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably Aduro Clean Technologies Inc. can carry it.
| Fiscal year end | FY24 | FY25 | FY26 |
|---|---|---|---|
| Cash and short-term investments | $2.1M | $5.0M | $27.7M |
| Interest coverage | −561.3x | −971.8x | −1,290.5x |
| Current ratio | 7.4x | 16.2x | 49.4x |
| Quick ratio | 7.4x | 16.2x | 49.4x |
| Total assets | $5.1M | $9.3M | $34.9M |
| Total liabilities | $0.4M | $0.8M | $13.3M |
| Shareholders' equity | $4.7M | $8.5M | $21.6M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✓ | ✓ |
| Share count didn't rise | — | ✕ | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | ✕ | ✕ |
| F-score | — / 3 | 3 / 7 | 3 / 7 |
| Accruals ratio | −32.3% | −31.5% | −55.7% |
| Altman Z'' | −3.85 | 0.90 | 0.29 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY24 | FY25 | FY26 |
|---|---|---|---|
| Income statement | |||
| Revenue | $0.2M | $0.2M | $0.1M |
| Research and development | $2.4M | $3.9M | $5.4M |
| Operating income | −$5.5M | −$8.6M | −$12.9M |
| Interest expense | $0.0M | $0.0M | $0.0M |
| Income tax | $0.0M | $0.0M | $0.0M |
| Net income | −$5.5M | −$8.7M | −$19.5M |
| Diluted EPS | −$0.27 | −$0.32 | −$0.61 |
| Diluted shares | 0.02B | 0.03B | 0.03B |
| Cash flow | |||
| Cash from operations | −$3.9M | −$6.4M | −$7.1M |
| Capital expenditure | $0.8M | $1.0M | $3.5M |
| Free cash flow | −$4.7M | −$7.5M | −$10.6M |
| Depreciation and amortization | $0.3M | $0.4M | $0.5M |
| Stock-based compensation | $1.1M | $2.3M | $4.6M |
| Balance sheet | |||
| Cash and short-term investments | $2.1M | $5.0M | $27.7M |
| Current assets | $2.7M | $6.2M | $28.5M |
| Current liabilities | $0.4M | $0.4M | $0.6M |
| Property and equipment, net | $2.3M | $3.0M | $6.1M |
| Total assets | $5.1M | $9.3M | $34.9M |
| Total liabilities | $0.4M | $0.8M | $13.3M |
| Shareholders' equity | $4.7M | $8.5M | $21.6M |
| Margins | |||
| Operating margin | −2,203.0% | −5,164.3% | −10,647.5% |
| EBITDA margin | −2,075.2% | −4,932.3% | −10,227.5% |
| Net margin | −2,203.7% | −5,254.2% | −16,062.7% |
| FCF margin | −1,883.7% | −4,509.6% | −8,773.9% |
| Returns | |||
| Return on capital employed | −116.3% | −96.0% | −37.6% |
| Return on equity | −118.1% | −131.8% | −129.1% |
| Return on assets | −107.9% | −120.9% | −88.1% |
| Return on tangible equity | −118.1% | −101.9% | −90.0% |
| Growth | |||
| Revenue growth | — | −33.7% | −26.8% |
| Share count change | — | 33.2% | 18.2% |
| Financial health | |||
| Interest coverage | −561.3x | −971.8x | −1,290.5x |
| Current ratio | 7.4x | 16.2x | 49.4x |
| Quick ratio | 7.4x | 16.2x | 49.4x |
| Capital allocation | |||
| Capex / revenue | 340.1% | 623.2% | 2,877.5% |
| Stock comp / revenue | 438.4% | 1,399.7% | 3,803.5% |
| Quality scores | |||
| Piotroski F-score | — | 3.0 | 3.0 |
| Altman Z'' | −3.8 | 0.9 | 0.3 |
| Accruals ratio | −32.3% | −31.5% | −55.7% |
Source: SEC EDGAR XBRL filings (CIK 0001863934). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in CAD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.